| Literature DB >> 35359974 |
Mireia López-Siles1, Carla Camprubí-Font1, Eva M Gómez Del Pulgar2, Miriam Sabat Mir3, David Busquets4, Yolanda Sanz2, Margarita Martinez-Medina1.
Abstract
Background & Aims: Adherent-invasive E. coli (AIEC) has largely been implicated in the pathogenesis of Crohn's disease (CD). E. coli strains with similar genetic backgrounds and virulence genes profiles have been associated with other intestinal disorders, such as ulcerative colitis (UC), colorectal cancer (CRC), and coeliac disease (CeD), but the role of AIEC in these diseases remains unexplored. We aimed to assess the distribution, abundance, and pathogenic features of AIEC in UC, CRC, and CeD.Entities:
Keywords: Crohn’s disease; adherent-invasive Escherichia coli; coeliac disease; colorectal cancer; ulcerative colitis
Mesh:
Year: 2022 PMID: 35359974 PMCID: PMC8960851 DOI: 10.3389/fimmu.2022.748839
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Characteristics of adult study subjects.
| Variable | H adults (N = 28) | CD (N = 20) | UC (N = 14) | CRC (N = 15) | |
|---|---|---|---|---|---|
| Age (mean years, range) | 44.7 [21–80] | 33.5 [15–49] | 45.4 [27–73] | 74.5 [56–86] | |
| Gender (N, %)* | Male | 12 (43%) | 7 (35%) | 8 (57.1%) | 12 (80%) |
| Female | 14 (50%) | 13 (65%) | 6 (42.9%) | 3 (20%) | |
| Smoker (N, %)* | No | nd | 3 (15%) | 8 (57.1%) | 11 (73.3%) |
| Former smoker | nd | 0 | 5 (35.7%) | 2 (13.3%) | |
| Yes | nd | 8 (40%) | 0 | 2 (13.3%) | |
| CD location (N, %)* | Ileal (I-CD) | na | 9 (45%) | na | na |
| Ileocolonic (IC-CD) | na | 7 (35%) | na | na | |
| Colonic (C-CD) | na | 3 (15%) | na | na | |
| UC extension (N, %) | Proctitis (E1) | na | na | 3 (21.4%) | na |
| Left-sided colitis (E2) | na | na | 9 (64.3%) | na | |
| Pancolitis (E3) | na | na | 2 (14.3%) | na | |
| CRC lesion location (N, %)* | No active disease | na | na | na | 1 (6.7%) |
| Sigmoid colon | na | na | na | 3 (20%) | |
| Descendent colon | na | na | na | 1 (6.7%) | |
| Cecum | na | na | na | 2 (13.3%) | |
| Rectum | na | na | na | 4 (26.7%) | |
| CRC type of lesion (N, %)* | Neoplasia | na | na | na | 8 (63.3%) |
| Dysplasia | na | na | na | 2 (13.3%) | |
| Severe dysplasia | na | na | na | 1 (6.7%) | |
| Neoplasia and metastasis | na | na | na | 1 (6.7%) | |
| Disease activity (N, %) | Active | na | 8 (40%) | 14 (100%) | na |
| Inactive | na | 7 (35%) | 0 | na | |
| Treatment (IBD) (N, %)** | None | na | 5 (25%) | 2 (14.3%) | na |
| Azathioprine | na | 7 (35%) | 2 (14.3%) | na | |
| Aminosalicylates | na | 1 (5%) | 6 (42.9%) | na | |
| Steroids | na | 0 | 2 (14.2%) | na | |
| Thiopurine | na | 1 (5%) | 0 | na | |
| Anti-TNF agent | na | 4 (20%) | 2 (14.2%) | na | |
| CRC treatment (N, %)* | None | na | na | na | 4 (26.7%) |
| Surgery | na | na | na | 3 (20%) | |
| Neoadjuvant | na | na | na | 4 (26.7%) | |
| Surgical resection (N, %)* | No | nd | 14 (70%) | 14 (100%) | 7 (46.7%) |
| Yes | nd | 3 (15%) | 0 | 8 (53.3%) | |
| Sample (N, %) | Ileum | 9 (32.1)% | 4 (20%) | 2 (14.3%) | 0 |
| Colon | 11 (39.3%) | 9 (45%) | 8 (57.1%) | 15 (100%) | |
| Ileum + Colon | 8 (28.6%) | 7 (35%) | 4 (28.6%) | 0 | |
H, healthy subjects; CD, Crohn’s disease; UC, ulcerative colitis; CRC, colorectal cancer; IBD, inflammatory bowel disease; na, not applicable; nd, no data available.
*Gender was available for 26/28 H subjects; Smoking habit was available for 11/20 CD, and 13/14 UC; Surgical resection information was available for 17/20 CD subjects; CD-location was available for 19/20 patients; CD-behavior was available for 9/20 CD patients; CD-disease activity was available for 15/20 CD patients, Treatment was available for 18/20 CD; CRC lesion location, type of lesion and treatment was recorded for 11/15, 12/15 and 11/15 patients, respectively.
**Subjects with combined therapy have been counted grouped as follows: Anti-TNF agents included patients with Anti-TNF plus steroids, aminosalicylate and enteral nutrition; Steroid included a patient with steroids and azathioprine and a patient with steroid and aminosalycilate.
Prevalence and abundance of indole-negative isolates obtained from each group of patients.
| Patients with indole negative isolates (%) | Abundance of indole negative isolates in patient with indole negative strains (%) | |
|---|---|---|
| H (N = 28) | 9 (32.1) | 1.0–77.1 |
| CD (N = 20) | 4 (20.0) | 0.5–5.9 |
| UC (N = 14) | 5 (35.7) | 3.2–20.7 |
| CRC (N = 15) | 6 (40.0) | 0.4–75.0 |
H, healthy subjects; CD, Crohn’s disease; UC, ulcerative colitis; CRC, colorectal cancer.
Figure 1AIEC prevalence in patients with different intestinal diseases and control subjects in biopsy samples (A) and feces (B). Prevalence has been calculated as the frequency of patients with at least one AIEC or AIEC-like strain recovered from any of the samples analyzed. Data from Crohn’s disease (CD) patients and healthy adults controls (H) has been extracted from a previous study (2). Bacteria from pediatric patients were previously isolated from fecal samples (29). IC-CD, ileocolonic Crohn’s disease; I-CD, ileal Crohn’s disease; C-CD, colonic Crohn’s disease; UC, ulcerative colitis; E1, proctitis; E2, left-sided colitis; E3, pancolitis; CRC, colorectal cancer; CeD, coeliac disease. ns, not significant; *p ≤ 0.05; **p ≤ 0.01.
AIEC prevalence (frequency of patients with AIEC and/or AIEC-like strains) and abundance (estimated AIEC and/or AIEC-like isolates/total Enterobacteriaceae) according to biopsy location.
| Condition | AIEC Prevalence | AIEC Abundance* | ||
|---|---|---|---|---|
| Ileum (N) | Colon (N) | Ileum (N) | Colon (N) | |
|
|
|
|
|
|
|
|
|
|
|
|
| I-/IC-CD | 55.5 (9) | 58.3 (12) | 0.104 ± 0.196 (5) | 0.117 ± 0.171 (7) |
| C-CD | 50.0 (2) | 25.0 (4) | 0.011 (1) | 0.037 (1) |
|
|
|
|
|
|
| E1 | 50.0 (2) | 0.0 (3) | 0.048 (1) | – |
| E2 | 50.0 (2) | 44.4 (9) | 0.042 (1) | 0.065 ± 0.095 (5) |
| E3 | 0.0 (2) | 0.0 (1) | – | – |
|
|
|
|
|
|
H, healthy subjects; CD, Crohn’s disease; UC, ulcerative colitis; CRC, colorectal cancer; I-CD, ileal Crohn’s disease; IC-CD, ileocolonic Crohn’s disease; C-CD, colonic Crohn’s disease; E1, proctitis; E2, left-sided colitits; E3, pancolitis.
*Abundance (mean ± standard deviation) was calculated only including those patients carrying AIEC and/or AIEC-like strains.
Figure 2AIEC abundance in patients with different intestinal diseases and control subjects. Abundance has been calculated as the proportion of AIEC and/or AIEC-like isolates with respect to the total Enterobacteriaceae isolates analyzed. Only data from patients with AIEC and/or AIEC-like has been considered. Data from Crohn’s disease (CD) patients and healthy controls (H) has been extracted from a previous study (2). Values indicate the abundance of patients with AIEC strains. For subjects with more than one sample analyzed, the mean abundance of all samples was used for calculations. IC-CD, ileocolonic Crohn’s disease; I-CD, ileal Crohn’s disease; C-CD, colonic Crohn’s disease; UC, ulcerative colitis; E1, proctitis; E2, left-sided colitis; CRC, colorectal cancer.
Virulence genes and phylogenetic group of AIEC and AIEC-like strains obtained from ulcerative colitis (UC) and colorectal cancer (CRC) patients.
| Disease | Isolate | Patient | Phylogroup |
|
|
|
|
|
|
|
|
|
|
|
| ADH_I (bacteria/cell) | INV_I (%) | REPL_I (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UC | PL23F02 | P107 | A | − | − | − | − | − | − | − | − | − | + | − | − | 19.8 ± 5.3 | 0.568 ± 0.006 | 641.8 ± 319.0 |
| UC | PL40G06 | P121 | B1 | − | + | + | − | + | − | + | − | + | + | + | − | 1.1 ± 0.2 | 0.142 ± 0.064 | 515.9 ± 335.7 |
| UC | GENAIEC1E01 (•) | HSC003 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 2.7 ± 1.7 | 0.201 ± 0.116 | 191.8 ± 136.4 |
| UC | GENAIEC2A03 (•) | HSC003 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 7.3 ± 2.5 | 0.377 ± 0.089 | 355.4 ± 208.2 |
| UC | GENAIEC3A06 (•) | HSC003 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 6.1 ± 3.0 | 0.165 ± 0.081 | 211.6 ± 80.3 |
| UC | GENAIEC3A08 (•) | HSC003 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 9.4 ± 3.6 | 0.150 ± 0.034 | 465.0 ± 284.4 |
| UC | GENAIEC3A09 (•) | HSC003 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 4.9 ± 1.6 | 0.265 ± 0.134 | 411.0 ± 102.1 |
| UC | GENAIEC13H3 | HSC009 | B1 | − | + | − | − | + | − | + | − | − | − | − | − | 2.9 ± 2.4 | 0.172 ± 0.034 | 302.3 ± 59.1 |
| UC | GENAIEC43B3 (*) | HT003 | B1 | + | − | − | − | + | − | − | + | + | + | − | + | 4.2 ± 2.2 | 0.188 ± 0.101 | 474.6 ± 128.4 |
| UC | GENAIEC43B6 (■) | HT003 | B1 | + | − | − | − | + | − | − | + | + | − | − | + | 6.1 ± 4.0 | 0.150 ± 0.078 | 403.1 ± 399.5 |
| UC | GENAIEC43E4 (*) | HT003 | B1 | + | − | − | − | + | − | − | + | + | + | − | + | 4.1 ± 0.8 | 0.129 ± 0.054 | 487.6 ± 89.5 |
| UC | GENAIEC43E9 (¤) | HT003 | B1 | + | − | − | − | + | − | − | + | + | − | − | + | 3.1 ± 2.6 | 0.146 ± 0.026 | 547.8 ± 157.7 |
| UC | GENAIEC43F5 (■) | HT003 | B1 | + | − | − | − | + | − | − | + | + | + | − | + | 2.2 ± 0.9 | 0.177 ± 0.072 | 547.8 ± 157.7 |
| CRC | GENAIEC41B6 (◊) | GENAIEC21 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 2.1 ± 0.9 | 0.313 ± 0.146 | 425.2 ± 278.2 |
| CRC | GENAIEC42B1 (◊) | GENAIEC21 | B1 | − | − | − | − | + | − | − | − | + | + | − | − | 2.8 ± 2.1 | 0.406 ± 0.472 | 210.3 ± 133.0 |
Symbols indicate those strains from a given subject that showed identical XbaI-pulsotype, (see ).
ADH_I, adhesion index; INV_I, invasion index ; REPL_I, replication index.
*Virulence genes and phylogenetic group available only for 15/16 adherent-invasive isolates confirmed to be E. coli.
Figure 3Adhesion (A), invasion (B) and replication indices (C) of AIEC and AIEC-like clones isolated from patients with different intestinal diseases and control subjects. Data from Crohn’s disease (CD) patients and healthy controls (H) has been extracted from a previous study (2). Only clonally independent strains are represented. A representative isolate has been chosen in cases that more than one isolate corresponded to the same clone. UC, ulcerative colitis; CRC, colorectal cancer. **p ≤ 0.01.
Figure 4Adhesion (A) and invasion (B) indices of E. coli isolates from patients with active and inactive celiac disease (CeD) and healthy (H) children (median indicated). Only non-AIEC strains included (N = 14 active CeD; N = 12 inactive CeD; N = 10 H children). *p ≤ 0.05; **p ≤ 0.01.